About 2 results found for searched term "Emibetuzumab" (0.216 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M24631 | Emibetuzumab | c-Met |
| LY2875358 | ||
| Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer. | ||
| M49472 | LY3164530 | EGFR/HER2 |
| LY-3164530 | ||
| LY3164530 is a bispecific antibody targeting c-MET/EGFR that fuses scFv (cetuximab) to the N-terminal end of the heavy chain of emibetuzumab, resulting in a 2+2 symmetric bis-antibody, which is of the IgG4 subtype, and has little to no associated effects such as ADCC. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
